Prospective Grant of an Exclusive Patent License: Exceptionally Selective D2 Dopamine Receptor Antagonists as Therapeutics

National Institutes of Health, HHS.

The National Institute of Neurological Disorders and Stroke and the National Center for Advancing Translational Sciences, institutes of the National Institutes of Health, Department of Health and Human Services, are contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Psycala Bio, Inc. (Psycala), incorporated in Delaware.

Only written comments and/or applications for a license which are received by the National Institute of Neurological Disorders and Stroke Technology Transfer on or before July 17, 2025 will be considered.

( printed page 23342)

Requests for copies of the patent applications, inquiries, and comments relating to the contemplated Exclusive Patent License should be directed to: Susan Ano, Ph.D., Chief, Technology Transfer Branch, Telephone: 301-435-5515; Email: [email protected].